AAVnerGene and Klotho Neurosciences Partner to Advance Gene Therapy for Neurological Diseases

AAVnerGene and Klotho’s Alliance

Announcement

AVVnerGene Inc., a Rockville, MD innovation-fueled biotech known for its remarkable technologies in AAV tissue-targeted delivery and manufacturing, and Klotho Neurosciences Inc. have entered a partnership to enhance the product’s potential. Together, AAVnerGene’s creative approach and Klotho’s precision product candidates will redesign the future of the healthcare market. The klotho’s current portfolio is focusing on cell and gene therapy, for which programs have been initiated using RNA and DNA as genomics-based diagnostics and therapeutic assays. Whereas the AAVnerGene platform covers AAVone, which is a single-plasmid, high-yield AAV production system that decreases manufacturing cost and excellent capsid engineering platform, ATHENA provides accurate tissue targeting.

Views and Statements

The CEO of KLTO, Dr. Joseph Sinkule, said, “We discussed previously about unlocking efficiency for discovering next generation method for manufacturing various of our designated gene therapy candidates, also the two other platform technologies introduced by AAVnerGene to catapult our product candidates into a clinical stage quickly at low cost and satisfying efficacy and purity in comparison to the recent state-of-the-art AAV manufacturing processes. We are eagerly waiting for the complementary longevity-based assets into our KLTO in concern to KLTO-101 for alzheimer’s and parkinson’s diseases, KLTO-303 for aging-related pathologies treatment, and KLTO-202 for ALS and different motor neuron diseases that promise a healthy and extended lifespan.”

Further, he added, “klotho trusts AAVnerGene’s method to perform fast, effective, and with minimal impurities, which will show low toxicity and high efficacy due to its excellent target tissue delivery. KLTO is looking forward to starting work with AAVnerGene for manufacturing various of our product candidates, poised with a tissue-specific promoter that will uplift our klotho gene. It will help us accelerate the concentration of the protein and produce the klotho protein, focusing on organs and tissues affected by the neuromuscular and neurologic diseases.”

Founder and CEO of AAVnerGene, Dr. Daozhan Yu, said, “AAV gene therapy is a guaranteed life-changing, one-time treatment. As of now, it's facing challenges due to its high dose (toxicity) and high medicine price. We had a vision of these problems six years ago, and our team was involved in the mission to solve them. With our two proprietary platforms, we can coordinate best with Klotho, a neuroscience-driven company. The klotho’s data on neuron longevity and safety is commendable, also it holds potential to provide promising treatment to many extreme diseases. We hope the partnership presents innovative and affordable drugs for patients with common and rare diseases.”